Safety Comparison: Clinical Evidence You Need to Know
Which Is Safer: Mounjaro or Wegovy Clinical Safety Data
Understanding which is safer between Mounjaro or Wegovy requires examining clinical trial data from both medications. Wegovy demonstrated a well-established safety profile in the STEP trials, with the most common side effects being gastrointestinal-related including nausea, diarrhoea, and vomiting. These effects typically occurred during dose escalation periods and often diminished over time as patients' bodies adapted to the medication.
Mounjaro's safety data from the SURMOUNT trials showed similar gastrointestinal side effects, though some studies suggested potentially higher rates of nausea and vomiting compared to GLP-1-only treatments. Both medications carry warnings for potential pancreatitis, thyroid tumours, and gallbladder problems, though these serious events remain rare. When considering which is safer, Mounjaro or Wegovy, your prescriber will evaluate your individual medical history, current medications, and risk factors.
UK Pricing for Mounjaro vs Wegovy Safety Assessment
At EverydayMeds, Wegovy pricing starts from £79.99 for the 0.25mg starter dose, progressing to £94.99 for 0.5mg, £99.99 for 1mg, £139.99 for 1.7mg, and £209.99 for the maintenance 2.4mg dose. Our Getting Started bundles like the Intro Duo (0.25mg & 0.5mg) cost £169.99, providing your first two months of treatment with convenient delivery. New customers can apply code FIRST40 at checkout, whilst returning customers use DOSE25 to access these competitive prices.
Mounjaro pricing varies by dose, but both treatments require the same comprehensive clinical assessment and prescriber review process. The safety evaluation includes reviewing your medical history, current medications, and any contraindications that might influence which is safer for your specific situation. This thorough assessment ensures you receive the most appropriate treatment whilst minimising potential risks and maximising therapeutic benefits.
Clinical Evidence: Which Is Safer Mounjaro or Wegovy Research
The STEP trials demonstrated Wegovy's safety profile across diverse patient populations, with Wilding et al., NEJM, 2021, reporting comprehensive adverse event data. Most participants experienced mild to moderate gastrointestinal effects, with discontinuation rates due to adverse events remaining relatively low throughout the study periods.
Mounjaro's SURMOUNT trials provided extensive safety data for tirzepatide, showing comparable overall safety patterns to other incretin-based therapies. Both medications underwent rigorous regulatory review by the MHRA, receiving approval based on their benefit-risk profiles in appropriate patient populations alongside lifestyle interventions.
How Wegovy Works: Understanding Safety Through Mechanism
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics natural incretin hormones to regulate blood sugar and appetite. This mechanism works by slowing gastric emptying, reducing appetite signals in the brain, and promoting feelings of satiety after smaller meals. The single-pathway approach of GLP-1 receptor activation provides a well-understood mechanism with predictable effects and side effect patterns. Understanding how Wegovy works helps explain why certain side effects occur, particularly the gastrointestinal symptoms that result from slowed gastric emptying. This mechanism-based understanding allows healthcare providers to better predict, prevent, and manage potential adverse effects during treatment.
UK Ordering Process: Safe Access to Both Treatments
EverydayMeds provides a comprehensive 3-minute online clinical assessment that evaluates your suitability for either Wegovy or Mounjaro based on medical history, current health status, and individual risk factors. Our qualified prescribers review each application within 3 working days (or 24 hours with express service), determining which treatment option may be safer and more appropriate for your circumstances. Once approved, genuine medications are delivered via next-day cold-chain delivery, maintaining product integrity and ensuring you receive authentic treatments. The assessment process includes specific questions about previous gastrointestinal issues, family history of relevant conditions, and current medications that might interact with either treatment. This thorough evaluation helps ensure the safest possible treatment selection whilst meeting all regulatory requirements for prescription-only medicine supply.
Storage and Practical Safety Considerations
Wegovy offers practical storage advantages with the ability to remain at room temperature for up to 6 weeks once removed from the fridge, compared to Mounjaro's 21-day room temperature limit. This extended stability reduces risks associated with temperature excursions during travel or temporary refrigeration issues. The FlexTouch pen design includes safety features like dose confirmation, automatic needle insertion, and clear dose displays to minimise administration errors. Proper storage and handling are crucial safety considerations, as expired or improperly stored medications may be less effective or potentially harmful. Both treatments require gradual dose escalation following specific schedules to minimise side effects and optimise safety profiles.
Which Is Safer Mounjaro or Wegovy: Individual Risk Assessment
Determining which is safer between Mounjaro or Wegovy depends entirely on individual patient factors rather than general population data alone. Patients with histories of gastrointestinal disorders, pancreatitis, or thyroid conditions require careful evaluation to determine appropriate treatment options. Age, concurrent medications, and existing medical conditions all influence the relative safety profile of each treatment.
EverydayMeds prescribers conduct comprehensive risk-benefit analyses, considering your complete medical picture before recommending either treatment. This personalised approach ensures the safest possible treatment selection whilst maximising potential therapeutic benefits. Both medications are available through our secure ordering system with ongoing clinical support throughout your treatment journey.
Expert Prescriber Support: Making the Right Safety Choice
Our qualified prescribers specialise in weight management medications and understand the nuances of choosing between Mounjaro and Wegovy based on individual safety considerations. Each consultation includes detailed discussion of potential side effects, monitoring requirements, and strategies for minimising risks whilst maximising treatment effectiveness. We provide ongoing support throughout your treatment, with easy access to clinical advice if you experience any concerning symptoms or require dose adjustments. Use code FIRST40 for new customers or DOSE25 for returning customers when ordering through https://everydaymeds.co.uk/collections/wegovy. Our GPhC-registered pharmacy (#9012878) ensures you receive genuine treatments with complete clinical oversight, making your safety our absolute priority throughout your weight management journey.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
